Quick comparison: Saxenda vs Ozempic (and Wegovy)
- Active ingredient
- Saxenda: liraglutide (GLP‑1 receptor agonist)
- Ozempic/Wegovy: semaglutide (GLP‑1 receptor agonist)
- Indication in Australia
- Saxenda: approved for chronic weight management
- Ozempic: approved for type 2 diabetes (not weight loss)
- Wegovy: semaglutide brand approved for weight management
- Dosing and convenience
- Saxenda: daily injection, titrated to 3.0 mg
- Semaglutide: weekly injection, titrated to therapeutic dose (Ozempic up to 1–2 mg for diabetes; Wegovy up to 2.4 mg for weight loss)
- Average weight loss (clinical trials)
- Saxenda 3 mg daily: ~8% at ~56 weeks (with lifestyle program)
- Wegovy 2.4 mg weekly: ~15% at ~68 weeks (with lifestyle program)
- Ozempic 0.5–1 mg weekly (diabetes doses): typically less than Wegovy, sometimes comparable to or greater than Saxenda depending on context
- Side effects and safety
- Similar GLP‑1 profile: nausea, vomiting, diarrhoea/constipation, abdominal pain most common
- Warnings: pancreatitis, gallbladder issues, kidney concerns from dehydration; avoid in personal/family history of medullary thyroid carcinoma or MEN2; discuss pregnancy plans
- Cost and access (private, varies by dose and pharmacy)
- Saxenda: often ~$350–$500+ per month
- Ozempic: roughly $130–$160 per pen privately; weight‑loss use is off‑label
- Wegovy: typically higher monthly cost than Ozempic; see local pricing
How they work: GLP‑1, appetite and metabolic effects
Saxenda (liraglutide) and Ozempic/Wegovy (semaglutide) activate the GLP‑1 receptor. This can reduce appetite and hunger, slow gastric emptying, and support improved glycaemic control. Semaglutide has higher receptor potency than liraglutide, which likely contributes to the larger average weight‑loss seen at therapeutic doses in trials.
Both medicines are intended to be used alongside dietary, activity and behavioural strategies. Lifestyle support remains important for maximising results and sustaining weight loss after dose stabilisation.
Dosing and titration schedules
- Saxenda (liraglutide) daily
- Typical titration: 0.6 mg daily, increasing weekly to 1.2 mg, 1.8 mg, 2.4 mg, then 3.0 mg as tolerated
- Missed doses: follow product guidance or your prescriber’s plan
- Semaglutide weekly
- Ozempic (diabetes): titration often 0.25 mg weekly → 0.5 mg → 1.0 mg (some use 2.0 mg for glycaemia)
- Wegovy (weight loss): titration to 2.4 mg weekly if tolerated
Your prescriber will individualise the schedule based on tolerability, goals, comorbidities and concurrent medicines.
Weight loss results: what to expect
- Saxenda 3 mg daily (SCALE program): average ~8% body‑weight loss at ~56 weeks, with lifestyle program
- Semaglutide 2.4 mg weekly (STEP program, Wegovy): average ~15% at ~68 weeks, with lifestyle program
- Ozempic diabetes doses: weight‑loss typically less than Wegovy but clinically meaningful for many; response varies
Early GI side effects usually settle after the titration phase. Clinicians often reassess response around 12–16 weeks at a therapeutic dose and again at 6–12 months. Sustained lifestyle changes improve the odds of reaching and maintaining targets.
Side effects, warnings and who should avoid
Common: nausea, vomiting, diarrhoea, constipation, abdominal pain, reflux, reduced appetite, headache, fatigue. Eat smaller meals, avoid high‑fat foods during titration, and follow your prescriber’s anti‑nausea strategies if needed.
Less common but serious: pancreatitis, gallbladder disease (e.g., cholelithiasis/cholecystitis), kidney issues (often secondary to dehydration), possible worsening of diabetic retinopathy with rapid glycaemic improvement (semaglutide), allergic reactions. Seek urgent care for severe or persistent abdominal pain, signs of dehydration, or suspected allergic reaction.
Contraindications/precautions: generally avoided in pregnancy and breastfeeding; personal/family history of medullary thyroid carcinoma or MEN2; previous pancreatitis; severe GI disease; dose adjustments or extra monitoring when combined with insulin or sulfonylureas due to hypoglycaemia risk. Discuss your medical history with a clinician.
Information here is general and does not replace personalised medical advice.
Who each option may suit
- Consider Saxenda if you:
- Prefer a daily routine and steady titration
- Previously did not tolerate semaglutide or cannot access Wegovy
- Are eligible for weight management and accept daily injections
- Consider semaglutide (Ozempic/Wegovy) if you:
- Prefer weekly dosing and the stronger average weight‑loss signal at therapeutic dose
- Are eligible for weight management (Wegovy) or have T2D needing Ozempic
- Can follow a careful titration to minimise GI effects
Suitability depends on medical history, current medications, response, side‑effect profile, budget and access. A prescriber can help you weigh these factors.
Access, PBS status and cost in Australia
- Prescription only: access via GPs, endocrinologists, obesity specialists or compliant telehealth providers
- PBS: Ozempic is PBS‑listed for type 2 diabetes criteria (not for weight loss); Saxenda and Wegovy are not PBS‑listed for weight loss at time of writing
- Private cost:
- Saxenda: often ~$350–$500+ per month depending on pharmacy and dose
- Ozempic: ~${'{'}130–160{'}'} per pen privately; monthly spend depends on dose and pens used
- Wegovy: typically higher monthly cost than Ozempic; check current pricing and availability
- Supply: semaglutide brands have faced periodic shortages; availability can change—your prescriber or pharmacist can advise current status
Alternatives to compare next
- Ozempic vs Wegovy (same drug, different dose and indication)
- Mounjaro vs Ozempic (tirzepatide dual‑agonist vs single GLP‑1)
- Semaglutide vs Tirzepatide
- Wegovy vs Saxenda
- Weight Loss Injections Australia (overview)
- GLP‑1 Australia Guide
Frequently asked questions
Is Ozempic better than Saxenda for weight loss?
Semaglutide (Wegovy brand for weight loss) has shown larger average weight loss than liraglutide (Saxenda). At Ozempic diabetes doses, weight loss is typically less than Wegovy but may exceed Saxenda for some people. The best option depends on eligibility, tolerability, goals and access.
Can Ozempic be prescribed for weight loss in Australia?
Ozempic is approved for type 2 diabetes. Some clinicians may prescribe it off‑label for weight management, but Wegovy is the semaglutide brand approved for weight loss. Your prescriber will advise based on local guidance and availability.
What if I can’t tolerate the side effects?
Discuss slower titration, dietary strategies and supportive medicines with your prescriber. If side effects persist, a different GLP‑1, a different dose, or a different class (e.g., tirzepatide) may be considered.
How long should I trial a dose before deciding it’s working?
Many clinicians reassess around 12–16 weeks at a therapeutic dose, then again over 6–12 months. Early appetite effects can appear during titration, but durable weight change is better judged after stabilisation.
Are compounded GLP‑1 products an option?
Australia has strict rules around compounding and supply of GLP‑1 products. Use approved products and follow your prescriber and TGA guidance. See our overview: Compounded Peptides Australia.
Who should not use these medicines?
Generally avoided in pregnancy or breastfeeding, in people with a personal/family history of medullary thyroid carcinoma or MEN2, previous pancreatitis, or severe GI disease. Always review your history and medications with a prescriber.
Get personalised help comparing Saxenda and Ozempic
Have a clinician review your goals, eligibility, dosing and likely costs. Expect a response within 1 business day.
By submitting, you consent to contact in line with our privacy policy.
Final takeaway
If weekly dosing and larger average weight‑loss are priorities—and you’re eligible—semaglutide (Wegovy for weight loss, Ozempic for diabetes) often has the edge. If you prefer daily dosing or did not tolerate semaglutide, Saxenda is a proven alternative. Your medical history, side‑effect tolerance, cost and local availability should guide the decision with a prescriber.